chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Starting the night of my first vaccine, I had nerve pain shooting from my shoulders up to the top of my head and behind my eyes, the occipital nerves (on both sides). It still hasn't gone away, sometimes the pain hurts so bad it drops me to the floor until it decides to calm down. Every menstrual cycle I have had since the vaccines has been extremely heavy and very painful, they make me sick and put me in bed for days. None of these conditions I've described have lightened up very much.
Felt fine for hours while sitting at computer and then I got a feeling that I had never had before in my life. It felt as if there was an elephant sitting on my chest.  No real pain. No panting. Just a real heavy chest.  It is not heartburn or upset stomach - I know how that feels.   It was uncomfortable and notice I got a look of distress in my face. That's when I laid down on the couch with feet up and put my hands above my head towards the floor. After about 1.5 hours, the feeling went away.  Haven't had anything else since then.
By that evening my arm started to swell. The next day the swelling had extended down to the olecranon with associated redness, warmth and pain. By day #2 even after having Benadryl and Pepcid, the swelling extended up the left side of the neck and collarbone. I went to Urgent care and was given steroids and told not to take the second dose. For two weeks, after vaccination and after the swelling receded, I had neuralgias and involuntary twitching of the left arm and hand. I have chronic left shoulder/arm pain since the vaccination that has not resolved and resulted in limited range of motion.
Fever (100°), shaking chills (severe), body aches, site soreness.
Around 2pm on Saturday I felt warm, flu like symptoms while at work . I left work went home started exp chills slept for 6 hrs, no appetite. I woke up Sunday still running low grade fever, sweats and really drained. Also my lymph node left side exp swelling went to PCP was told could be the protein.
Information has been received from a pharmacist referring to a 69 year old female patient. There was no concomitant medication, medical history, nor drug reactions/allergies. The patient's concurrent condition was not provided. On an unspecified date in "2012", the patient was vaccinated with a first dose of PNEUMOVAX 23 (dose, route, lot # and expiration date were unknown) intramuscularly. On 15-NOV-2016, the patient was inadvertently vaccinated with a second dose of PNEUMOVAX 23 (lot # M038216 with expiration date 09-MAY-2018, dose unknown) intramuscularly. On an unknown date in November 2016 after receiving the second dose of PNEUMOVAX 23, the patient developed "swelling, pain and warmth" at the injection site. The pharmacist reported that she recommended the patient ice affected area and take TYLENOL or ADVIL, but didn't know if the patient iced the area or took any medications. On 17-NOV-2016, the pharmacist called the patient back and the patient reported that she saw her physician and that no treatment was provided. On the same day, the patient reported to the pharmacist that the "swelling is going down and the warmth and pain are going away." No lab diagnostic studies was performed. The causality assessment between PNEUMOVAX 23 and "swelling, pain and warmth" at the injection site was not reported. Additional information has been requested.
Initial and follow-up information has been received from a nurse practitioner concerning a 22 year old female with latex and seaonal allergies who in September 2007, was vaccinated with a first dose of GARDASIL. On approximately 18-SEP-2007 the patient presented to the nurse practitioner with pain at the injection site, (unknown which arm), and acne of the face and opposite arm. The patient does not have a history of acne. At the time of the report the patient's outcome was unknown. Additional information is not expected.
This spontaneous report as received from a company representative refers to a female patient of unknown age. On an unknown date the patient was vaccinated with GARDASIL (intramuscular) dose 3. Dose and lot number were not reported. On an unknown date, after the patient had received the third dose in series, the patient experienced nausea and swelling. The patient visited due to the events the emergency room (ER). The outcome of nausea and swelling was unknown. Reporter causality was not reported. Additional information has been requested.
The vaccine was administered too high on the shoulder.  Within 2 hours a report was made. symptoms were pain, weakness, tenderness of shoulder joint and upper arm
As the patient was checking out with mom, she fell back and hit her head. and  appeared to start seizing and her eyes went to the back of her head and her body started to contract and started to shake in tremors for 10 seconds . Doctor was notified and pt was monitored.
Dizzy, lightheaded, pallor of lips, BP 86/48 HR 60 supine, after 30 minute 106/66 HR 66 sitting
fine maculopapular rash on anterior neck anterior chest arms and legs and trunk, sore throat and swelling of skin of anterior neck.
REDNESS OF FINGERTIPS ON ALL FOUR FINGERS (BEHIND FINGERNAILS) AND SEVERE SWELLING OF TWO FINGERS WITH DISCOLORATION R HAND. ALSO FEW PAINFUL VESICLES ON FINGERTIPS OR FINGER PADS. SWELLING SUBSIDED IN FIVE DAYS. THE FINGER TIPS REMAIN RED AND FINGERS APPEAR TO BE HEALING. THE SWELLING OCCURRED ABOUT 2 MOS. AFTER INJ. THE FINGER TIPS REMAIN RED. VESICLES APPEAR TO SUBSIDE. I'M WONDERING IF ANYONE EVER REPORTED SUCH FINDINGS.
HPV was given on her right deltoid after the flu shot. Pt was unresponsive for 25 seconds. Patient responded appropriately to her name and where she was and also stated that she just received some shot.  This was the patient's last dose. She had no reaction to her previous doses.
I experienced a swollen bubble under my right arm, and pain in my arm that lasted for 3 months. I have fully recovered with no lingering symptoms.
Hives broke out all over arms, legs, abdomen - two nights in a row, only at night. Disappearing by 10am for the most part.
About 5 minutes after recieving sitting in car unable to respond to questions for about 10 minutes. Then back to self.
Day 8 (March 6) - 2" square redness around injection site; some itchiness and heat these persisted through Day 9 (March 7) Day 10 (March 8) - redness faded slightly; slight itchiness persisted through Day 12 (March 10) continued gradual fading; Day 15 (March 13) - redness gone
Information has been received from a consumer concerning her 6 month old son with no past medical history and no known allergies who on 6/27/82 was vaccinated with a dose of MMR (second generation). There was no concomitant medication. On 6/28/82, the next day, the patient's gland on the right side of his neck swelled up. The patient also had a fever and his white blood cells were elevated. The swelling lasted several months. The patient sought unspecified medical attention. Additional information has been requested.
The patient had received her 2nd Pfizer dose on 2/2/22 and was not due to receive her 1st Pfizer booster until 7/2/22. This 1st booster was given 2 weeks and 2 days early. Pt. denied any abnormal/negative side effects after vaccine through 6/29/22, when I spoke with her, upon noticing the administration error.
COVID-19 breakthrough case.  8/22/21: Patient arrived at the ER due to worsening dyspnea and non-productive cough, he noted a fever of 101 at home. As his dyspnea worsened, he states he used his home CPAP and started feeling better. Reports testing positive for COVID on 8/21/21. admitted to ICU on 8/22. Note: Patient previously received Pfizer COVID-19 vaccine, first dose on 2/25/2021 Lot # EL9263 and 2nd dose on 3/18/2021 Lot # EN6198. Diagnosed with acute hypoxic respiratory failure, COVID-19 pneumonia. 8/30/21: Patient discharged home
Patient was administered a HIB vaccine  on 8/26/21  that had expired on 8/6/21. expiration was not realized until after administration of vaccine. Child is well and no adverse reactions related to  administering expired vaccine. Mom, provider and office manager informed right away. Plan to re-admister vaccine
The vial's expiration date was 01-Apr-2022, and it was moved from the freezer to the fridge on 23-Apr-2022 and administered on 23-Apr-2022; The vial's expiration date was 01-Apr-2022 and it was administered on 23-Apr-2022; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (The vial's expiration date was 01-Apr-2022 and it was administered on 23-Apr-2022) and PRODUCT STORAGE ERROR (The vial's expiration date was 01-Apr-2022, and it was moved from the freezer to the fridge on 23-Apr-2022 and administered on 23-Apr-2022) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) (batch no. 026L21B) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Apr-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 23-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (The vial's expiration date was 01-Apr-2022 and it was administered on 23-Apr-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial's expiration date was 01-Apr-2022, and it was moved from the freezer to the fridge on 23-Apr-2022 and administered on 23-Apr-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (The vial's expiration date was 01-Apr-2022 and it was administered on 23-Apr-2022) and PRODUCT STORAGE ERROR (The vial's expiration date was 01-Apr-2022, and it was moved from the freezer to the fridge on 23-Apr-2022 and administered on 23-Apr-2022) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.   For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication reported. It was reported that they had an excursion where Moderna product was administered past the expiration date. Expiration date of the vial was 01-Apr-2022. Product did not experience temperature excursions while stored in the freezer or fridge. The vial was moved from the freezer to the fridge on 23-Apr-2022 at approximately 10:00 am. Total amount of time the vial was exposed to room temperature before administration: Per Rph- approximately 15 minutes. No treatment medication details reported.
Information has been received from a physician concerning a 12 week old female infant who was vaccinated with the first dose of ROTATEQ. The patient developed rash immediately after administration. Additional information has been requested.
After receiving vaccine and during 15 minute watch time, patient seeing provider for unrelated issue reported hoarseness, flushing of face and chest pressure.    Stated she had a similar reaction in the past to cortisone injection.
Diarrhea (acute) -fever (TYLENOL, every 4-6hrs). Diarrhea (chronic, 5 months) -feeding difficulties (ongoing). Lactose intolerance. Sucrose intolerance (chronic). Reflux.
Increased menstral bleeding & excessive clotting beginning the day after receiving the Covid booster. Bleeding continued for approximately 6 weeks, with cessation of abnormal bleeding for approximately 5 weeks, followed by active uterine hemorrhaging resulting in 2 day hospital stay requiring blood transfusions & additional medications to attempt cessation of bleeding. Uterine hemorrhaging during this episode lasted approximately 12 days.
A couple of years ago a titanium chip was injected into my left breast to help mark/locate a cyst. Last week, after my vaccine, I experienced pinching/stabbing pain around area of titanium chip.; This is a spontaneous report from a contactable consumer. This 62-year-old patient of unspecified gender received dose 1 of BNT162B2 (PFIZER BIONTECH COVID-19 MRNA VACCINE) via an unspecified route of administration on 02Mar2021 at 16:30 (at the age of 62-years-old) as a single dose in the left arm for COVID-19 immunization. Medical history included a titanium chip injected into left breast to help mark/locate a cyst on an unspecified date a couple of years ago, type 2 diabetes, psoriasis, and depression. The patient did not receive any other vaccines within 4 weeks prior to the vaccine. Prior to vaccination the patient had not been diagnosed with COVID-19. Concomitant medications included metformin and glyburide from unknown dates for unknown indications. The patient previously received sulfa antibiotics from an unknown date for an unknown indication and experienced allergy. The patient had an allergy to pineapple. On an unspecified date "last week" after receiving BNT162B2 the patient experienced pinching/stabbing around the area of the titanium chip. It gradually lessened and by day 7 post vaccine it seemed to have stopped. There was no swelling, redness, or rash. The event was reported as non-serious. The patient was not hospitalized for the event. The patient did not receive any treatment for the event. The outcome of pinching/stabbing around the area of the titanium chip was recovered. It was also reported that since the vaccination, the patient had not been tested for COVID-19.  The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow-up.
This spontaneous case was reported by a consumer and describes the occurrence of CHANGE OF BOWEL HABIT (bowel habit changes, continued but did not get worst after the booster), MYALGIA (Achy) and FATIGUE (Tired for a few days) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 065F21A) for COVID-19 vaccination. No Medical History information was reported. On 07-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Nov-2021, the patient experienced CHANGE OF BOWEL HABIT (bowel habit changes, continued but did not get worst after the booster), MYALGIA (Achy) and FATIGUE (Tired for a few days). On 09-Nov-2021, MYALGIA (Achy) and FATIGUE (Tired for a few days) had resolved. At the time of the report, CHANGE OF BOWEL HABIT (bowel habit changes, continued but did not get worst after the booster) had not resolved. Concomitant medication of the patient was not reported. No treatment information was provided by the reporter. Her bowel habit never went back to normal. The patient had not seen a doctor. This case was linked to MOD-2022-455073, MOD-2022-455337 (Patient Link).
it is unknown if the consumer had antibodies for the Measles component of the vaccine; This spontaneous report has been received from a female patient of unknown age referring to herself. The patient's pertinent medical history, drug reactions/allergies and concomitant medication were not reported.  On an unknown date (reported as over 40 years ago), the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (strength, dose, route of administration, lot# and expiration date were not reported) for prophylaxis.   At the reporting time, the patient stated she still had antibodies for mumps and rubella. It was unknown if the patient had antibodies for the measles component of the vaccine (measles antibody negative). The patient wanted to know if there was a single dose measles vaccine. The outcome of the event was unknown.  The relationship between the event measles antibody negative and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) was not reported.
got Shingles; This case was reported by a other health professional via call center representative and described the occurrence of shingles in a patient who received Herpes zoster (Shingrix) for prophylaxis.   In 2020, the patient received Shingrix. On an unknown date, 2 days after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details provided were as follows: The case was reported for patient's friend. Age at vaccination was not reported. Pharmacy Intern had reported that a patient came in wanting the Shingrix vaccine. The patient mentioned that his/her friend received their Shingrix vaccine last year in 2020 and 2 days later experienced Shingles. Patient was curious to know more before Shingrix. Pharmacy Intern confirmed that the patient had not started the Shingrix series. Pharmacy intern was unable to provide any of the friends details or vaccine information. Pharmacy intern called to inquire if any studies performed on Shingrix and Shingles after first dose. The pharmacy intern declined to follow-up.
Fever greater than 104, chills, headache, joint pain, muscle aches, rash on left arm & chest, menstrual period  post menopause
whooping cough; Initial information received on 11-Mar-2022 regarding an unsolicited valid serious case was received from other health professional.  This case involves Adult and unknown gender patient who experienced whooping cough while receiving vaccine diphtheria, tetanus and acellular pertussis vaccine.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received an unknown dose of suspect diphtheria, tetanus and acellular pertussis vaccine produced by unknown manufacturer (lot number and expiry date: not reported) in unknown administration site as prophylactic vaccination.  On an unknown date the patient developed a serious whooping cough (pertussis) (unknown latency) following the administration of diphtheria and tetanus and acellular pertussis vaccine. This event was assessed as medically significant.  Action taken with diphtheria, tetanus and acellular pertussis vaccine was not applicable.  It was not reported if the patient received a corrective treatment for the event (whooping cough).  At time of reporting, the outcome was Unknown for the event whooping cough.; Sender's Comments: Sanofi company comment dated 14-Mar-2022: This case concerns an adult and unknown gender patient who experienced whooping cough after receiving vaccine diphtheria, tetanus and acellular pertussis vaccine. A significant temporal relationship cannot be established due to lack of information on event onset date and vaccination date. Information regarding condition at the time of vaccination, medical history, concomitant medication, would be needed to rule out the alternative etiology. Based on the reported information, the role of an individual vaccine cannot be assessed.
About 12 hours after vaccination tried to sleep, but stated sweating and shaking. Sought his mother at 5AM, screaming, sobbing, incoherent. Ran into street in underwear, restrained by EMS. Febrile 102. Resolved promptly.
Frequent urination; UTI; This is a spontaneous report from a Pfizer sponsored program. A contactable consumer (patient) reported that a 34-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) 1st dose on 11Mar2021 12:30 PM and 2nd dose on 08Apr2021 12:30PM, both at single dose via an unknown route in left arm for Covid-19 immunization. Medical history included Attention deficit hyperactivity disorder (ADHD), Nonalcoholic fatty liver disease (NAFLD), Obsessive-compulsive disorder (OCD), allergies to ammonium chloride and watermelons. Concomitant drug was "none". The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other medications within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. About a week after the first vaccine a developed a need to urinate frequently, every 5-20 minutes. Patient presumed it was a UTI and took steps to treat it. Event onset date was 16Mar2021 01:00. The symptoms abated about four days before the second vaccine. The symptoms returned on 21Apr021, four days after the second vaccination. Treatment received for the adverse event included antibiotics, pain reliever, antihistamines. Outcome of the events was resolved with sequel. Since the vaccination, the patient was not been tested for COVID-19.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
No additonal AE reported; administration of an expired GARDASIL 9 [Lot: S023476, Exp: 3/26/2022] to a patient on 04APRIL2022; This spontaneous report was received from a nurse practitioner referring to a patient of unknown age and gender. The patient's concurrent conditions, medical history, concomitant medications, and drug reactions/allergies were not reported.  On 04-APR-2022, the patient was administered an expired hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (dose and anatomical location were not reported; lot # S023476 has been validated to be a valid lot # for hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9), expiration date 26-MAR-2022) as prophylaxis.   The reporter confirmed that vaccine was not involved in any temperature excursions and was stored within the recommended storage range until administration. The reporter was provided with supported disclaimer from post expiry memo. No adverse events were reported
Developed sudden hearing loss in left ear approx. 2 months after receiving 1 does of JJ covid-19 vaccine  Treated with a round of oral steroids day after onset of hearing loss symptoms for 10 days, followed by direct steroid injections into ear weekly for 8 weeks  While some hearing was restored eventually there is significant, permanent hearing loss in left ear
vaccine expired on 2/12/23 and vaccine was given on 3/2/23, no adverse effects noted
A report was received from a health care professional on 25 November 2003, concerning a 7 month old male vaccinee who inadvertently received Fluvirin on 20 November 2003. On 20 November 2003 the vaccinee inadvertently received 0.25 ml of Fluvirin. At the time of the report no adverse events had been reported. There was insufficient information to determine the reporter's causality assessment. Update 1, 11 March 2004: Further information received from a health care professional indicated that the vaccinee did not experience any adverse reaction at the time of the report. No follow up pending, all information received. See Ref: PJP200301183, PJP200400053, PJP200400052, PJP200400051, PJP200400050, PJP200400049, PJP200400048, PJP200400047, PJP200400045, PJP200400044, PJP200400043, PJP200400042, PJP200400041, PJP200400040, PJP200400039, PJP200400038, PJP200400037, PJP200400036.